113209-89-5

Basic information

• Product Name: Pyridine, 4-chloro-5-fluoro-2-methyl-, 1-oxide
• Synonyms: Pyridine, 4-chloro-5-fluoro-2-methyl-, 1-oxide;4-chloro-5-fluoro-2-methylpyridine N-oxide
• CAS NO: 113209-89-5
• Molecular Formula: C6H5ClFNO
• Molecular Weight: 161.563
• Mol File: 113209-89-5.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Pyridine, 4-chloro-5-fluoro-2-methyl-, 1-oxide(CAS DataBase Reference)
• NIST Chemistry Reference: Pyridine, 4-chloro-5-fluoro-2-methyl-, 1-oxide(113209-89-5)
• EPA Substance Registry System: Pyridine, 4-chloro-5-fluoro-2-methyl-, 1-oxide(113209-89-5)

Safety Data

• Hazardous Substances Data: 113209-89-5(Hazardous Substances Data)

Upstream product

• 45673-79-8 2‐methyl‐5‐fluoropyridine 1‐oxide 
• 31181-53-0 2‐methyl‐5‐fluoropyridine 
• 80287-53-2 5-Amino-2-methylpyridine 
• 113209-88-4 5-fluoro-2-methyl-4-nitropyridine 1-oxide 

Downstream Products

• 113209-90-8 4-chloro-5-fluoro-2-(hydroxymethyl)pyridine 

Relevant articles and documents

NOVEL OXALYL PIPERAZINES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV)

The present invention relates generally to novel antiviral agents. Specifically, the present invention relates to compounds which can inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV replication cycle, compositions comprising such compounds, methods for inhibiting HBV viral replication, methods for treating or preventing HBV infection, and processes and intermediates for making the compounds.

Quinolizinone type compounds

Antibacterial compounds having the formula STR1 and the pharmaceutically acceptable salts, esters and amides thereof, preferred examples of which include those compounds wherein A is =CR6 --; R1 is cycloalkyl of from three to eight carbon atoms or substituted phenyl; R2 is selected from the group consisting of STR2 R3 is halogen; R4 is hydrogen, loweralkyl, a pharmaceutically acceptable cation, or a prodrug ester group; R5 is hydrogen, loweralkyl, halo(loweralkyl), or --NR13 R14 ; and R6 is halogen, loweralkyl, halo(loweralkyl), hydroxy-substituted loweralkyl, loweralkoxy(loweralkyl), loweralkoxy, or amino(loweralkyl), as well as pharmaceutical compositions containing such compounds and the use of the same in the treatment of bacterial infections.

2-[[(4-Amino-2-pyridyl)methyl]sulfinyl]benzimidazole H+/K+-ATPase inhibitors. The relationship between pyridine basicity, stability, and activity

The benzimidazole sulfoxide class of antisecretory H+/K+-ATPase inhibitors need to possess high stability under neutral physiological conditions yet rearrange rapidly at low pH to the active sulfenamide 2. Since the initial reaction involves internal nucleophilic attack by the pyridine nitrogen, control of the pyridine pK(a) is critical. In this paper we show that by utilizing the powerful electron-donating effect of a 4-amino substituent on the pyridine, moderated by the electron-withdrawing effect of a 3- or 5-halogen substituent, a combination of high potency (as inhibitors of histamine-stimulated gastric acid secretion) and good stability under physiological conditions can be obtained. Furthermore, the role of the steric interaction between the 3/5-substituents and the 4-substituent in modifying the electron-donating ability of the 4-amino group is exemplified, and additional factors affecting stability are identified. One compound, in particular, 2-[[(3-chloro-4-morpholino-2-pyridyl)methyl]sulfinyl]-5-methoxy-(1H)- benzimidazole (3a, SK and F 95601), was chosen for further development and evaluation in man.